Correction: Biomark Res 9, 9 (2021)
https://doi.org/10.1186/s40364-021-00262-3
In the original article [1], there was a mistake in Fig. 1e as published. The pictures of GAPDH of PC9 and HCC827 cells in Fig. 1e were misused by accident during figure assembly. The corrected Fig. 1e appears below with new histograms.
Significant upregulation of APCDD1L-AS1 in icotinib-resistant LUAD cells. a The icotinib sensitivity in icotinib-resistant LUAD cells and their parental cells treated with different concentrations of icotinib for 96 h was determined by MTT assay. PC9/IcoRL: PC9 low-dose icotinib-resistant cells; PC9/IcoRH: PC9 high-dose icotinib-resistant cells; HCC827/IcoRL: HCC827 low-dose icotinib-resistant cells; HCC827/IcoRH: HCC827 high-dose icotinib-resistant cells. b The cell viability of both the parental cells and their icotinib-resistant cells after treated with icotinib (10 μM) for 24, 48, 72 and 96 h was detected by MTT assay. c The colony formation ability of the parental cells and their icotinib-resistant cells under different concentrations of icotinib was analyzed using colony formation assay. d The subcutaneous tumor mouse models of icotinib-resistant cells and their parental cells were treated with or without icotinib. Average tumor volume for each group was measured (n = 3). e The level of EGFR expression and phosphorylation in the parental cells and their icotinib-resistant cells was evaluated by western blot. f Four upregulated lncRNAs identified by volcano plots in PC9/IcoRL cells and PC9/IcoRH cells comparing with PC9 cells. g The list of top four upregulated lncRNAs in PC9/IcoRL cells and PC9/IcoRH cells comparing with PC9 cells by transcriptome sequencing. h The expression level of lncRNAs, APCDD1L-AS1, PAX8-AS1, GAS5 and lnc-GSDMD, was determined in the parental cells and their icotinib-resistant cells by qRT-PCR. The mean ± SD of triplicate experiments were plotted, *P < 0.05, **P < 0.01, ***P < 0.001, n.s., not statistically significant
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.
Reference
Jie Wu, et al. LncRNA APCDD1L-AS1 induces icotinib resistance by inhibition of EGFR autophagic degradation via the miR-1322/miR-1972/ miR-324-3p-SIRT5 axis in lung adenocarcinoma. Biomark Res. 2021;9:9. https://doi.org/10.1186/s40364-021-00262-3.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Wu, J., Zheng, C., Wang, Y. et al. Correction: LncRNA APCDD1L-AS1 induces icotinib resistance by inhibition of EGFR autophagic degradation via the miR-1322/miR-1972/ miR-324-3p-SIRT5 axis in lung adenocarcinoma. Biomark Res 11, 51 (2023). https://doi.org/10.1186/s40364-023-00496-3
Published:
DOI: https://doi.org/10.1186/s40364-023-00496-3